All Stories

  1. Multi‐Institutional Study of ALK‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

    Article • American Journal of Hematology, September 2025, Wiley

    Dr. Marcus Watkins

  2. Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study

    Article • Hematological Oncology, April 2025, Wiley

    Dr. Marcus Watkins

  3. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study

    Article • Blood Cancer Journal, October 2024, Springer Science + Business Media

    Dr. Marcus Watkins, Andrea Anampa-Guzmán

  4. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

    Article • Blood Advances, July 2024, American Society of Hematology

    Dr. Marcus Watkins

  5. Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

    Article • Blood Advances, January 2024, American Society of Hematology

    Dr. Marcus Watkins

  6. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study

    Article • Blood Advances, November 2023, American Society of Hematology

    Dr. Marcus Watkins, Andrea Anampa-Guzmán

  7. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

    Article • Cancer Research Communications, November 2023, American Association for Cancer Research (AACR)

    Dr. Marcus Watkins

  8. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

    Article • Blood Advances, September 2023, American Society of Hematology

    Dr. Marcus Watkins

  9. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

    Article • Haematologica, September 2023, Ferrata Storti Foundation (Haematologica)

    Dr. Marcus Watkins

  10. Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report

    Article • JCO Precision Oncology, September 2023, American Society of Clinical Oncology (ASCO)

    Dr. Marcus Watkins

  11. FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV max as a predictive biomarker in frontline treatment of mantle cell lymphoma

    Article • Leukemia & Lymphoma, July 2023, Taylor & Francis

    Dr. Marcus Watkins

  12. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies

    Article • Clinical Lymphoma Myeloma & Leukemia, July 2023, Elsevier

    Dr. Marcus Watkins

  13. Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

    Article • American Journal of Hematology, January 2023, Wiley

    Dr. Marcus Watkins

  14. Evaluation of Breast Implant–Associated Anaplastic Large Cell Lymphoma With Whole Exome and Genome Sequencing

    Article • Aesthetic Surgery Journal, November 2022, Oxford University Press (OUP)

    Dr. Marcus Watkins

  15. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma

    Article • Leukemia & Lymphoma, November 2022, Taylor & Francis

    Dr. Marcus Watkins

  16. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

    Article • Clinical Lymphoma Myeloma & Leukemia, July 2022, Elsevier

    Dr. Marcus Watkins

  17. Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

    Article • Cancers, June 2022, MDPI AG

    Dr. Marcus Watkins

  18. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

    Article • Blood, March 2022, American Society of Hematology

    Dr. Marcus Watkins

  19. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

    Article • Blood Advances, March 2022, American Society of Hematology

    Dr. Marcus Watkins

  20. COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

    Article • Leukemia & Lymphoma, February 2022, Taylor & Francis

    Dr. Marcus Watkins

  21. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

    Article • Blood, January 2022, American Society of Hematology

    Dr. Marcus Watkins

  22. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

    Article • July 2021, Cold Spring Harbor Laboratory Press

    Dr. Marcus Watkins

  23. A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma

    Article • Med, February 2021, Elsevier

    Dr. Marcus Watkins

  24. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma

    Article • Biology of Blood and Marrow Transplantation, December 2020, Elsevier

    Dr. Marcus Watkins

  25. A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma

    Article • Leukemia & Lymphoma, October 2020, Taylor & Francis

    Dr. Marcus Watkins

  26. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

    Article • Expert Opinion on Biological Therapy, June 2020, Taylor & Francis

    Dr. Marcus Watkins

  27. Fifty shades of GATA2 mutation: A Case of Plasmablastic Lymphoma, Non-tuberculous Mycobacterial Infection, and Myelodysplastic Syndrome

    Article • Clinical Lymphoma Myeloma & Leukemia, May 2019, Elsevier

    Dr. Marcus Watkins

  28. A patient with an apparent appendicitis in Amyand hernia was found to have an unexpected pathology.

    Article • International Journal of Case Reports and Images, January 2019, Edorium Journals Pvt. Ltd.

    Dr. Marcus Watkins

  29. Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes

    Article • Journal of Ultrasound in Medicine, July 2018, Wiley

    Dr. Marcus Watkins

  30. New CD19-targeted treatment for patients non-Hodgkin B-cell lymphomas

    Article • Expert Opinion on Investigational Drugs, July 2018, Taylor & Francis

    Dr. Marcus Watkins

  31. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2018, Elsevier

    Dr. Marcus Watkins

  32. Heterozygous deletion of both sclerostin (Sost) and connexin43 (Gja1) genes in mice is not sufficient to impair cortical bone modeling

    Article • PLOS One, November 2017, PLOS

    Dr. Marcus Watkins

  33. N-cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage-Specific

    Article • Journal of Bone and Mineral Research, March 2017, Wiley

    Dr. Marcus Watkins

  34. p62 Is Required for Stem Cell/Progenitor Retention through Inhibition of IKK/NF-κB/Ccl4 Signaling at the Bone Marrow Macrophage-Osteoblast Niche

    Article • Cell Reports, December 2014, Elsevier

    Dr. Marcus Watkins

  35. Postnatal ablation of osteoblast Smad4 enhances proliferative responses to canonical Wnt signaling through interactions with β-catenin

    Article • Journal of Cell Science, October 2013, The Company of Biologists

    Dr. Marcus Watkins

  36. Molecular Mechanisms of Osteoblast/Osteocyte Regulation by Connexin43

    Article • Calcified Tissue International, June 2013, Springer Science + Business Media

    Dr. Marcus Watkins

  37. Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice

    Article • Bone, October 2012, Elsevier

    Dr. Marcus Watkins

  38. Enhanced Periosteal and Endocortical Responses to Axial Tibial Compression Loading in Conditional Connexin43 Deficient Mice

    Article • PLOS One, September 2012, PLOS

    Dr. Marcus Watkins

  39. Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis

    Article • Journal of Bone and Mineral Research, August 2011, Wiley

    Dr. Marcus Watkins

  40. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling

    Article • Molecular Biology of the Cell, April 2011, American Society for Cell Biology (ASCB)

    Dr. Marcus Watkins

  41. N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms

    Article • Journal of Cell Science, July 2010, The Company of Biologists

    Dr. Marcus Watkins

  42. Microfibril-associated Glycoprotein-1, an Extracellular Matrix Regulator of Bone Remodeling

    Article • Journal of Biological Chemistry, May 2010, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Marcus Watkins

  43. Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series

    Article • Calcified Tissue International, June 2009, Springer Science + Business Media

    Dr. Marcus Watkins

  44. The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans

    Article • Human Molecular Genetics, November 2007, Oxford University Press (OUP)

    Dr. Marcus Watkins

  45. Accentuated Ovariectomy-Induced Bone Loss and Altered Osteogenesis in Heterozygous N-Cadherin Null Mice

    Article • Journal of Bone and Mineral Research, December 2006, Wiley

    Dr. Marcus Watkins

  46. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43

    Article • Journal of Cell Science, October 2006, The Company of Biologists

    Dr. Marcus Watkins

  47. The use of Agar as a novel filler for monolithic matrices produced using hot melt extrusion

    Article • European Journal of Pharmaceutics and Biopharmaceutics, August 2006, Elsevier

    Dr. Marcus Watkins

  48. Nutrient regulates Tor1 nuclear localization and association with rDNA promoter

    Article • Nature, August 2006, Springer Science + Business Media

    Dr. Marcus Watkins